Manufacturing mesenchymal stromal cells for phase I clinical trials

被引：41

作者：

Hanley, Patrick J. ^{[1
,2
]}

Mei, Zhuyong ^{[1
,2
]}

Cabreira-Hansen, Maria da Graca ^{[3
]}

Klis, Mariola ^{[1
,2
]}

Li, Wei ^{[1
,2
]}

Zhao, Yali ^{[1
,2
]}

Durett, April G. ^{[1
,2
]}

Zheng, Xingwu ^{[4
]}

Wang, Yongping ^{[4
,5
]}

Gee, Adrian P. ^{[1
,2
]}

Horwitz, Edwin M. ^{[4
,5
]}

机构：

[1] Texas Childrens Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[2] Methodist Hosp, Houston, TX 77030 USA

[3] St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA

[4] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[5] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

CYTOTHERAPY | 2013年 / 15卷 / 04期

基金：

美国国家卫生研究院;

关键词：

clinical trials; Good Manufacturing Practices; mesenchymal stromal cells; phase I trials; BONE-MARROW; STEM-CELLS; BLOOD; CHILDREN; CULTURE; THERAPY; LIVER;

D O I：

10.1016/j.jcyt.2012.09.007

中图分类号：

Q813 [细胞工程];

学科分类号：

摘要：

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells capable of differentiating into adipocytes, osteoblasts and chondroblasts as well as secreting a vast array of soluble mediators. This potentially makes MSCs important mediators of a variety of therapeutic applications. They are actively under evaluation for immunomodulatory purposes such as graft-versus-host disease and Crohn's disease as well as regenerative applications such as stroke and congestive heart failure. We report our method of generating clinical-grade MSCs together with suggestions gathered from manufacturing experience in our Good Manufacturing Practices facility.

引用

页码：416 / 422

页数：7

共 27 条

[1] Immunosuppressive Properties of Mesenchymal Stem Cells
Abumaree, Mohamed
Al Jumah, Mohammed
Pace, Rishika A.
Kalionis, Bill
[J]. STEM CELL REVIEWS AND REPORTS, 2012, 8 (02) : 375 - 392
[2] Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1
Battula, Venkata Lokesh
Treml, Sabrina
Bareiss, Petra M.
Gieseke, Friederike
Roelofs, Helene
de Zwart, Peter
Mueller, Ingo
Schewe, Bernhard
Skutella, Thomas
Fibbe, Willem E.
Kanz, Lothar
Buehring, Hans-Joerg
[J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02): : 173 - 184
[3] Bieback K., 2011, STEM CELLS INT, V2010
[4] Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow
Campagnoli, C
Roberts, IAG
Kumar, S
Bennett, PR
Bellantuono, I
Fisk, NM
[J]. BLOOD, 2001, 98 (08) : 2396 - 2402
[5] MESENCHYMAL STEM-CELLS
CAPLAN, AI
[J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) : 641 - 650
[6] Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow
D'Ippolito, G
Schiller, PC
Ricordi, C
Roos, BA
Howard, GA
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (07) : 1115 - 1122
[7] Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement
Dominici, M.
Le Blanc, K.
Mueller, I.
Slaper-Cortenbach, I.
Marini, F. C.
Krause, D. S.
Deans, R. J.
Keating, A.
Prockop, D. J.
Horwitz, E. M.
[J]. CYTOTHERAPY, 2006, 8 (04) : 315 - 317
[8] Optimising Human Mesenchymal Stem Cell Numbers for Clinical Application: A Literature Review
Fossett, E.
Khan, W. S.
[J]. STEM CELLS INTERNATIONAL, 2012, 2012
[9] FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
[10] Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
Götherström, C
Ringdén, O
Westgren, M
Tammik, C
Le Blanc, K
[J]. BONE MARROW TRANSPLANTATION, 2003, 32 (03) : 265 - 272

← 1 2 3 →